Does the media prefer REGN or AMGN?

In the previous week, Amgen had 10 more articles in the media than Regeneron Pharmaceuticals. MarketBeat recorded 38 mentions for Amgen and 28 mentions for Regeneron Pharmaceuticals. Amgen's average media sentiment score of 1.23 beat Regeneron Pharmaceuticals' score of 0.50 indicating that Amgen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Regeneron Pharmaceuticals 9 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 5 Negative mention(s) 0 Very Negative mention(s) Neutral Amgen 25 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to REGN or GILD?

In the previous week, Gilead Sciences had 9 more articles in the media than Regeneron Pharmaceuticals. MarketBeat recorded 37 mentions for Gilead Sciences and 28 mentions for Regeneron Pharmaceuticals. Gilead Sciences' average media sentiment score of 1.00 beat Regeneron Pharmaceuticals' score of 0.50 indicating that Gilead Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Regeneron Pharmaceuticals 9 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 5 Negative mention(s) 0 Very Negative mention(s) Neutral Gilead Sciences 20 Very Positive mention(s) 5 Positive mention(s) 1 Neutral mention(s) 6 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer REGN or MRNA?

In the previous week, Regeneron Pharmaceuticals had 2 more articles in the media than Moderna. MarketBeat recorded 28 mentions for Regeneron Pharmaceuticals and 26 mentions for Moderna. Moderna's average media sentiment score of 0.74 beat Regeneron Pharmaceuticals' score of 0.50 indicating that Moderna is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Regeneron Pharmaceuticals 9 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 5 Negative mention(s) 0 Very Negative mention(s) Neutral Moderna 12 Very Positive mention(s) 7 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Regeneron Pharmaceuticals (REGN) Competitors

$664.52 -3.43 (-0.51%)

Closing price 07/10/2026 04:00 PM Eastern

Extended Trading

$664.00 -0.52 (-0.08%)

As of 07/10/2026 07:20 PM Eastern

Compare

REGN vs. AMGN, GILD, MRNA, NTLA, and VIR

Should you buy Regeneron Pharmaceuticals stock or one of its competitors? MarketBeat compares Regeneron Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Regeneron Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Moderna (MRNA), Intellia Therapeutics (NTLA), and Vir Biotechnology (VIR). These companies are all part of the "med - biomed/gene" industry.

How does Regeneron Pharmaceuticals compare to Amgen?

Regeneron Pharmaceuticals (NASDAQ:REGN) and Amgen (NASDAQ:AMGN) are both large-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, valuation, media sentiment, analyst recommendations, institutional ownership and risk.

In the previous week, Amgen had 10 more articles in the media than Regeneron Pharmaceuticals. MarketBeat recorded 38 mentions for Amgen and 28 mentions for Regeneron Pharmaceuticals. Amgen's average media sentiment score of 1.23 beat Regeneron Pharmaceuticals' score of 0.50 indicating that Amgen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Regeneron Pharmaceuticals	9 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	5 Negative mention(s)	0 Very Negative mention(s)	Neutral
Amgen	25 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Regeneron Pharmaceuticals has a beta of 0.24, indicating that its stock price is 76% less volatile than the broader market. Comparatively, Amgen has a beta of 0.41, indicating that its stock price is 59% less volatile than the broader market.

Regeneron Pharmaceuticals has a net margin of 29.65% compared to Amgen's net margin of 20.96%. Amgen's return on equity of 137.41% beat Regeneron Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Regeneron Pharmaceuticals	29.65%	13.16%	10.17%
Amgen	20.96%	137.41%	13.28%

Amgen has higher revenue and earnings than Regeneron Pharmaceuticals. Regeneron Pharmaceuticals is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Regeneron Pharmaceuticals	$14.34B	4.90	$4.50B	$41.04	16.19
Amgen	$36.75B	5.34	$7.71B	$14.37	25.29

83.3% of Regeneron Pharmaceuticals shares are held by institutional investors. Comparatively, 76.5% of Amgen shares are held by institutional investors. 7.0% of Regeneron Pharmaceuticals shares are held by insiders. Comparatively, 0.9% of Amgen shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Regeneron Pharmaceuticals pays an annual dividend of $3.76 per share and has a dividend yield of 0.6%. Amgen pays an annual dividend of $10.08 per share and has a dividend yield of 2.8%. Regeneron Pharmaceuticals pays out 9.2% of its earnings in the form of a dividend. Amgen pays out 70.1% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Amgen has raised its dividend for 14 consecutive years. Amgen is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Regeneron Pharmaceuticals currently has a consensus target price of $787.67, indicating a potential upside of 18.53%. Amgen has a consensus target price of $355.73, indicating a potential downside of 2.11%. Given Regeneron Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts clearly believe Regeneron Pharmaceuticals is more favorable than Amgen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Regeneron Pharmaceuticals	0 Sell rating(s)	9 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	2.70
Amgen	2 Sell rating(s)	15 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.43

Summary

Amgen beats Regeneron Pharmaceuticals on 12 of the 20 factors compared between the two stocks.

How does Regeneron Pharmaceuticals compare to Gilead Sciences?

Regeneron Pharmaceuticals (NASDAQ:REGN) and Gilead Sciences (NASDAQ:GILD) are both large-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, dividends, profitability, media sentiment, institutional ownership and valuation.

Regeneron Pharmaceuticals presently has a consensus price target of $787.67, indicating a potential upside of 18.53%. Gilead Sciences has a consensus price target of $159.04, indicating a potential upside of 22.50%. Given Gilead Sciences' stronger consensus rating and higher probable upside, analysts clearly believe Gilead Sciences is more favorable than Regeneron Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Regeneron Pharmaceuticals	0 Sell rating(s)	9 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	2.70
Gilead Sciences	0 Sell rating(s)	3 Hold rating(s)	26 Buy rating(s)	0 Strong Buy rating(s)	2.90

Regeneron Pharmaceuticals has a beta of 0.24, indicating that its stock price is 76% less volatile than the broader market. Comparatively, Gilead Sciences has a beta of 0.32, indicating that its stock price is 68% less volatile than the broader market.

Gilead Sciences has a net margin of 30.99% compared to Regeneron Pharmaceuticals' net margin of 29.65%. Gilead Sciences' return on equity of 48.19% beat Regeneron Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Regeneron Pharmaceuticals	29.65%	13.16%	10.17%
Gilead Sciences	30.99%	48.19%	18.28%

In the previous week, Gilead Sciences had 9 more articles in the media than Regeneron Pharmaceuticals. MarketBeat recorded 37 mentions for Gilead Sciences and 28 mentions for Regeneron Pharmaceuticals. Gilead Sciences' average media sentiment score of 1.00 beat Regeneron Pharmaceuticals' score of 0.50 indicating that Gilead Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Regeneron Pharmaceuticals	9 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	5 Negative mention(s)	0 Very Negative mention(s)	Neutral
Gilead Sciences	20 Very Positive mention(s)	5 Positive mention(s)	1 Neutral mention(s)	6 Negative mention(s)	0 Very Negative mention(s)	Positive

Gilead Sciences has higher revenue and earnings than Regeneron Pharmaceuticals. Regeneron Pharmaceuticals is trading at a lower price-to-earnings ratio than Gilead Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Regeneron Pharmaceuticals	$14.34B	4.90	$4.50B	$41.04	16.19
Gilead Sciences	$29.44B	5.47	$8.51B	$7.34	17.69

83.3% of Regeneron Pharmaceuticals shares are owned by institutional investors. Comparatively, 83.7% of Gilead Sciences shares are owned by institutional investors. 7.0% of Regeneron Pharmaceuticals shares are owned by insiders. Comparatively, 0.3% of Gilead Sciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Regeneron Pharmaceuticals pays an annual dividend of $3.76 per share and has a dividend yield of 0.6%. Gilead Sciences pays an annual dividend of $3.28 per share and has a dividend yield of 2.5%. Regeneron Pharmaceuticals pays out 9.2% of its earnings in the form of a dividend. Gilead Sciences pays out 44.7% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Gilead Sciences has increased its dividend for 10 consecutive years. Gilead Sciences is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Summary

Gilead Sciences beats Regeneron Pharmaceuticals on 16 of the 20 factors compared between the two stocks.

How does Regeneron Pharmaceuticals compare to Moderna?

Regeneron Pharmaceuticals (NASDAQ:REGN) and Moderna (NASDAQ:MRNA) are both large-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, valuation, profitability, risk, institutional ownership, analyst recommendations, earnings and dividends.

Regeneron Pharmaceuticals has a net margin of 29.65% compared to Moderna's net margin of -143.55%. Regeneron Pharmaceuticals' return on equity of 13.16% beat Moderna's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Regeneron Pharmaceuticals	29.65%	13.16%	10.17%
Moderna	-143.55%	-26.64%	-19.32%

Regeneron Pharmaceuticals currently has a consensus price target of $787.67, suggesting a potential upside of 18.53%. Moderna has a consensus price target of $38.27, suggesting a potential downside of 43.95%. Given Regeneron Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Regeneron Pharmaceuticals is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Regeneron Pharmaceuticals	0 Sell rating(s)	9 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	2.70
Moderna	5 Sell rating(s)	11 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.83

In the previous week, Regeneron Pharmaceuticals had 2 more articles in the media than Moderna. MarketBeat recorded 28 mentions for Regeneron Pharmaceuticals and 26 mentions for Moderna. Moderna's average media sentiment score of 0.74 beat Regeneron Pharmaceuticals' score of 0.50 indicating that Moderna is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Regeneron Pharmaceuticals	9 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	5 Negative mention(s)	0 Very Negative mention(s)	Neutral
Moderna	12 Very Positive mention(s)	7 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Regeneron Pharmaceuticals has a beta of 0.24, indicating that its stock price is 76% less volatile than the broader market. Comparatively, Moderna has a beta of 0.94, indicating that its stock price is 6% less volatile than the broader market.

83.3% of Regeneron Pharmaceuticals shares are owned by institutional investors. Comparatively, 75.3% of Moderna shares are owned by institutional investors. 7.0% of Regeneron Pharmaceuticals shares are owned by insiders. Comparatively, 10.8% of Moderna shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Regeneron Pharmaceuticals has higher revenue and earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Regeneron Pharmaceuticals	$14.34B	4.90	$4.50B	$41.04	16.19
Moderna	$1.94B	13.93	-$2.82B	-$8.15	N/A

Summary

Regeneron Pharmaceuticals beats Moderna on 13 of the 17 factors compared between the two stocks.

How does Regeneron Pharmaceuticals compare to Intellia Therapeutics?

Intellia Therapeutics (NASDAQ:NTLA) and Regeneron Pharmaceuticals (NASDAQ:REGN) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, analyst recommendations, media sentiment, dividends, earnings and risk.

In the previous week, Regeneron Pharmaceuticals had 13 more articles in the media than Intellia Therapeutics. MarketBeat recorded 28 mentions for Regeneron Pharmaceuticals and 15 mentions for Intellia Therapeutics. Regeneron Pharmaceuticals' average media sentiment score of 0.50 beat Intellia Therapeutics' score of 0.41 indicating that Regeneron Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Intellia Therapeutics	3 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Regeneron Pharmaceuticals	9 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	5 Negative mention(s)	0 Very Negative mention(s)	Neutral

Regeneron Pharmaceuticals has a net margin of 29.65% compared to Intellia Therapeutics' net margin of -597.04%. Regeneron Pharmaceuticals' return on equity of 13.16% beat Intellia Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Intellia Therapeutics	-597.04%	-57.47%	-46.24%
Regeneron Pharmaceuticals	29.65%	13.16%	10.17%

Intellia Therapeutics currently has a consensus price target of $20.67, suggesting a potential upside of 45.39%. Regeneron Pharmaceuticals has a consensus price target of $787.67, suggesting a potential upside of 18.53%. Given Intellia Therapeutics' higher possible upside, analysts clearly believe Intellia Therapeutics is more favorable than Regeneron Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Intellia Therapeutics	3 Sell rating(s)	10 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.35
Regeneron Pharmaceuticals	0 Sell rating(s)	9 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	2.70

88.8% of Intellia Therapeutics shares are owned by institutional investors. Comparatively, 83.3% of Regeneron Pharmaceuticals shares are owned by institutional investors. 3.5% of Intellia Therapeutics shares are owned by insiders. Comparatively, 7.0% of Regeneron Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Regeneron Pharmaceuticals has higher revenue and earnings than Intellia Therapeutics. Intellia Therapeutics is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Intellia Therapeutics	$67.67M	29.36	-$412.69M	-$3.54	N/A
Regeneron Pharmaceuticals	$14.34B	4.90	$4.50B	$41.04	16.19

Intellia Therapeutics has a beta of 1.77, indicating that its share price is 77% more volatile than the broader market. Comparatively, Regeneron Pharmaceuticals has a beta of 0.24, indicating that its share price is 76% less volatile than the broader market.

Summary

Regeneron Pharmaceuticals beats Intellia Therapeutics on 12 of the 16 factors compared between the two stocks.

How does Regeneron Pharmaceuticals compare to Vir Biotechnology?

Regeneron Pharmaceuticals (NASDAQ:REGN) and Vir Biotechnology (NASDAQ:VIR) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, dividends, valuation, profitability, risk, earnings, institutional ownership and media sentiment.

83.3% of Regeneron Pharmaceuticals shares are owned by institutional investors. Comparatively, 65.3% of Vir Biotechnology shares are owned by institutional investors. 7.0% of Regeneron Pharmaceuticals shares are owned by insiders. Comparatively, 2.9% of Vir Biotechnology shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Regeneron Pharmaceuticals has a beta of 0.24, suggesting that its share price is 76% less volatile than the broader market. Comparatively, Vir Biotechnology has a beta of 1.62, suggesting that its share price is 62% more volatile than the broader market.

Regeneron Pharmaceuticals presently has a consensus target price of $787.67, indicating a potential upside of 18.53%. Vir Biotechnology has a consensus target price of $20.88, indicating a potential upside of 109.59%. Given Vir Biotechnology's stronger consensus rating and higher possible upside, analysts clearly believe Vir Biotechnology is more favorable than Regeneron Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Regeneron Pharmaceuticals	0 Sell rating(s)	9 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	2.70
Vir Biotechnology	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89

In the previous week, Regeneron Pharmaceuticals had 27 more articles in the media than Vir Biotechnology. MarketBeat recorded 28 mentions for Regeneron Pharmaceuticals and 1 mentions for Vir Biotechnology. Vir Biotechnology's average media sentiment score of 1.87 beat Regeneron Pharmaceuticals' score of 0.50 indicating that Vir Biotechnology is being referred to more favorably in the news media.

Company	Overall Sentiment
Regeneron Pharmaceuticals	Neutral
Vir Biotechnology	Very Positive

Regeneron Pharmaceuticals has a net margin of 29.65% compared to Vir Biotechnology's net margin of -638.88%. Regeneron Pharmaceuticals' return on equity of 13.16% beat Vir Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Regeneron Pharmaceuticals	29.65%	13.16%	10.17%
Vir Biotechnology	-638.88%	-53.31%	-41.76%

Regeneron Pharmaceuticals has higher revenue and earnings than Vir Biotechnology. Vir Biotechnology is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Regeneron Pharmaceuticals	$14.34B	4.90	$4.50B	$41.04	16.19
Vir Biotechnology	$68.56M	24.50	-$437.99M	-$3.13	N/A

Summary

Regeneron Pharmaceuticals beats Vir Biotechnology on 11 of the 16 factors compared between the two stocks.

Get Regeneron Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding REGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

REGN vs. The Competition

Export

Metric	Regeneron Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$70.62B	$3.78B	$7.12B	$12.61B
Dividend Yield	0.56%	2.17%	2.68%	7.83%
P/E Ratio	16.19	21.27	27.19	24.56
Price / Sales	4.90	323.90	590.19	121.71
Price / Cash	15.91	147.64	49.34	60.04
Price / Book	2.25	8.41	10.90	6.39
Net Income	$4.50B	$23.85M	$3.57B	$331.44M
7 Day Performance	1.57%	-0.76%	-0.25%	0.37%
1 Month Performance	8.67%	8.80%	4.53%	0.54%
1 Year Performance	17.05%	53.61%	29.18%	21.93%

Regeneron Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
REGN Regeneron Pharmaceuticals	4.6842 of 5 stars	$664.52 -0.5%	$787.67 +18.5%	+18.7%	$70.62B	$14.34B	16.19	15,410	Analyst Forecast Insider Trade
AMGN Amgen	4.1035 of 5 stars	$361.33 -0.2%	$355.50 -1.6%	+21.0%	$195.01B	$36.75B	25.14	31,500	Positive News Analyst Forecast
GILD Gilead Sciences	4.8824 of 5 stars	$125.97 -0.3%	$158.41 +25.8%	+13.3%	$156.40B	$29.44B	17.16	17,000	Positive News Analyst Forecast
MRNA Moderna	2.1822 of 5 stars	$72.50 +3.5%	$37.13 -48.8%	+99.2%	$28.77B	$1.94B	N/A	4,700	Trending News Analyst Forecast Options Volume
NTLA Intellia Therapeutics	3.3961 of 5 stars	$17.24 +1.9%	$20.46 +18.7%	+16.9%	$2.41B	$67.67M	N/A	600	News Coverage Positive News Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:REGN) was last updated on 7/11/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Regeneron Pharmaceuticals (REGN) Competitors

REGN vs. AMGN, GILD, MRNA, NTLA, and VIR

How does Regeneron Pharmaceuticals compare to Amgen?

Summary

How does Regeneron Pharmaceuticals compare to Gilead Sciences?

Summary

How does Regeneron Pharmaceuticals compare to Moderna?

Summary

How does Regeneron Pharmaceuticals compare to Intellia Therapeutics?

Summary

How does Regeneron Pharmaceuticals compare to Vir Biotechnology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

REGN vs. The Competition

Regeneron Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Regeneron Pharmaceuticals (REGN) Competitors

REGN vs. AMGN, GILD, MRNA, NTLA, and VIR

How does Regeneron Pharmaceuticals compare to Amgen?

Does the media prefer REGN or AMGN?

Which has more volatility and risk, REGN or AMGN?

Is REGN or AMGN more profitable?

Which has better valuation & earnings, REGN or AMGN?

Do insiders and institutionals have more ownership in REGN or AMGN?

Is REGN or AMGN a better dividend stock?

Do analysts recommend REGN or AMGN?

Summary

How does Regeneron Pharmaceuticals compare to Gilead Sciences?

Do analysts prefer REGN or GILD?

Which has more risk and volatility, REGN or GILD?

Is REGN or GILD more profitable?

Does the media refer more to REGN or GILD?

Which has higher earnings and valuation, REGN or GILD?

Do insiders & institutionals believe in REGN or GILD?

Is REGN or GILD a better dividend stock?

Summary

How does Regeneron Pharmaceuticals compare to Moderna?

Is REGN or MRNA more profitable?

Do analysts rate REGN or MRNA?

Does the media prefer REGN or MRNA?

Which has more risk & volatility, REGN or MRNA?

Do institutionals and insiders hold more shares of REGN or MRNA?

Which has stronger earnings and valuation, REGN or MRNA?

Summary

How does Regeneron Pharmaceuticals compare to Intellia Therapeutics?

Does the media favor NTLA or REGN?

Is NTLA or REGN more profitable?

Do analysts recommend NTLA or REGN?

Do institutionals and insiders hold more shares of NTLA or REGN?

Which has higher earnings & valuation, NTLA or REGN?

Which has more risk and volatility, NTLA or REGN?

Summary

How does Regeneron Pharmaceuticals compare to Vir Biotechnology?

Do institutionals & insiders have more ownership in REGN or VIR?

Which has more volatility and risk, REGN or VIR?

Do analysts prefer REGN or VIR?

Does the media favor REGN or VIR?

Is REGN or VIR more profitable?

Which has higher earnings and valuation, REGN or VIR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

REGN vs. The Competition

Regeneron Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools